NAUT vs NCEL

Nautilus Biotechnology, Inc. vs NewcelX Ltd. — Valuation Comparison 2026

NAUT

Biotechnology
Nautilus Biotechnology, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$2.60
Last close
Models
7/13
Active
VS

NCEL

Biotechnology
NewcelX Ltd.
Quality
1.7
out of 10
Value Trap
12
SAFE
Price
$3.54
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NAUT Fair ValueNAUT Upside NCEL Fair ValueNCEL Upside
Bayesian DCF Intrinsic $0.67 -74.3% $0.94 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.86 -67.0% $1.53 -55.6%
PWERM Option-Based $2.54 -2.2% $2.43 -29.5%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAUT vs NCEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAUT vs NCEL — Which Stock Is More Undervalued?

NAUT scores higher with a 4.3/10 quality rating vs NCEL's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nautilus Biotechnology, Inc. (NAUT) and NewcelX Ltd. (NCEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAUT currently trades at $2.60 with a QOC of 4.3/10, while NCEL trades at $3.54 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).